1. Home
  2. PINE vs TRDA Comparison

PINE vs TRDA Comparison

Compare PINE & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpine Income Property Trust Inc.

PINE

Alpine Income Property Trust Inc.

N/A

Current Price

$16.64

Market Cap

317.1M

Sector

Real Estate

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$4.80

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PINE
TRDA
Founded
2019
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.1M
275.3M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
PINE
TRDA
Price
$16.64
$4.80
Analyst Decision
Buy
Strong Buy
Analyst Count
11
8
Target Price
★ $19.90
$19.00
AVG Volume (30 Days)
184.4K
★ 413.2K
Earning Date
10-22-2026
11-05-2026
Dividend Yield
★ 7.68%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.42
N/A
Revenue
★ $60,532,000.00
$25,421,000.00
Revenue This Year
$31.91
N/A
Revenue Next Year
$10.40
$156.96
P/E Ratio
$40.21
★ N/A
Revenue Growth
★ 15.90
N/A
52 Week Low
$15.29
$4.11
52 Week High
$21.99
$16.45

Technical Indicators

Market Signals
Indicator
PINE
TRDA
Relative Strength Index (RSI) 42.58 45.14
Support Level $16.62 $4.18
Resistance Level $19.93 $7.89
Average True Range (ATR) 0.63 0.46
MACD 0.03 0.08
Stochastic Oscillator 37.48 43.84

Price Performance

Historical Comparison
PINE
TRDA

About PINE Alpine Income Property Trust Inc.

Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: